UNITY BIOTECHNOLOGY INC (UBX) Fundamental Analysis & Valuation

NASDAQ:UBX • US91381U2006

0.2001 USD
-0.1 (-33.41%)
At close: Jul 8, 2025
0.1754 USD
-0.02 (-12.34%)
After Hours: 7/8/2025, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This UBX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to UBX. UBX was compared to 520 industry peers in the Biotechnology industry. Both the profitability and financial health of UBX have multiple concerns. UBX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. UBX Profitability Analysis

1.1 Basic Checks

  • UBX had negative earnings in the past year.
  • UBX had a negative operating cash flow in the past year.
  • UBX had negative earnings in each of the past 5 years.
  • In the past 5 years UBX always reported negative operating cash flow.
UBX Yearly Net Income VS EBIT VS OCF VS FCFUBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -90.63%, UBX is doing worse than 73.12% of the companies in the same industry.
Industry RankSector Rank
ROA -90.63%
ROE N/A
ROIC N/A
ROA(3y)-55.15%
ROA(5y)-54.83%
ROE(3y)-206.62%
ROE(5y)-167.01%
ROIC(3y)N/A
ROIC(5y)N/A
UBX Yearly ROA, ROE, ROICUBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for UBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UBX Yearly Profit, Operating, Gross MarginsUBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. UBX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for UBX has been increased compared to 1 year ago.
  • UBX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for UBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UBX Yearly Shares OutstandingUBX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
UBX Yearly Total Debt VS Total AssetsUBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • UBX has an Altman-Z score of -26.49. This is a bad value and indicates that UBX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of UBX (-26.49) is worse than 88.35% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.49
ROIC/WACCN/A
WACCN/A
UBX Yearly LT Debt VS Equity VS FCFUBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.95 indicates that UBX should not have too much problems paying its short term obligations.
  • UBX has a Current ratio of 1.95. This is in the lower half of the industry: UBX underperforms 76.52% of its industry peers.
  • A Quick Ratio of 1.95 indicates that UBX should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.95, UBX is doing worse than 74.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.95
Quick Ratio 1.95
UBX Yearly Current Assets VS Current LiabilitesUBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. UBX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.94% over the past year.
EPS 1Y (TTM)23.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, UBX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.84% on average per year.
  • Based on estimates for the next years, UBX will show a very negative growth in Revenue. The Revenue will decrease by -16.43% on average per year.
EPS Next Y4.15%
EPS Next 2Y17.45%
EPS Next 3Y13.8%
EPS Next 5Y15.84%
Revenue Next Year-100%
Revenue Next 2Y-53.8%
Revenue Next 3Y-19.92%
Revenue Next 5Y-16.43%

3.3 Evolution

UBX Yearly Revenue VS EstimatesUBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2022 2024 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M
UBX Yearly EPS VS EstimatesUBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. UBX Valuation Analysis

4.1 Price/Earnings Ratio

  • UBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UBX Price Earnings VS Forward Price EarningsUBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UBX Per share dataUBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

  • UBX's earnings are expected to grow with 13.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.45%
EPS Next 3Y13.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UBX Dividend Analysis

5.1 Amount

  • UBX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

UBX Fundamentals: All Metrics, Ratios and Statistics

UNITY BIOTECHNOLOGY INC

NASDAQ:UBX (7/8/2025, 8:00:01 PM)

After market: 0.1754 -0.02 (-12.34%)

0.2001

-0.1 (-33.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-22
Earnings (Next)08-12
Inst Owners17.19%
Inst Owner Change-99.81%
Ins Owners1.57%
Ins Owner Change0%
Market Cap3.44M
Revenue(TTM)N/A
Net Income(TTM)-27.50M
Analysts77.5
Price Target3.06 (1429.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.38%
Min EPS beat(2)-22.33%
Max EPS beat(2)-6.44%
EPS beat(4)2
Avg EPS beat(4)3.37%
Min EPS beat(4)-22.33%
Max EPS beat(4)33.56%
EPS beat(8)6
Avg EPS beat(8)17.28%
EPS beat(12)10
Avg EPS beat(12)18.78%
EPS beat(16)12
Avg EPS beat(16)18.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.69%
PT rev (3m)-40%
EPS NQ rev (1m)-33.33%
EPS NQ rev (3m)-27.66%
EPS NY rev (1m)-18.24%
EPS NY rev (3m)-12.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-1.28
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -90.63%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.15%
ROA(5y)-54.83%
ROE(3y)-206.62%
ROE(5y)-167.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.95
Quick Ratio 1.95
Altman-Z -26.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1.78%
Cap/Depr(5y)6.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.47%
EPS Next Y4.15%
EPS Next 2Y17.45%
EPS Next 3Y13.8%
EPS Next 5Y15.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-53.8%
Revenue Next 3Y-19.92%
Revenue Next 5Y-16.43%
EBIT growth 1Y21.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.3%
EBIT Next 3Y-7.08%
EBIT Next 5YN/A
FCF growth 1Y54.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.8%
OCF growth 3YN/A
OCF growth 5YN/A

UNITY BIOTECHNOLOGY INC / UBX FAQ

What is the fundamental rating for UBX stock?

ChartMill assigns a fundamental rating of 1 / 10 to UBX.


What is the valuation status of UNITY BIOTECHNOLOGY INC (UBX) stock?

ChartMill assigns a valuation rating of 0 / 10 to UNITY BIOTECHNOLOGY INC (UBX). This can be considered as Overvalued.


What is the profitability of UBX stock?

UNITY BIOTECHNOLOGY INC (UBX) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for UBX stock?

The Earnings per Share (EPS) of UNITY BIOTECHNOLOGY INC (UBX) is expected to grow by 4.15% in the next year.